News and Press Releases
Press releases
Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy
Press ReleaseTMX Newsfile | Mar 2, 2026 7:00 AM EST Theralase(R) Demonstrates Additive Anti-Cancer Effect in Bladder Cancer In-Vitro Model when Light-Activated Ruvidar(R) is Combined with Interferon Toronto, Ontario–(Newsfile Corp. – March 2, 2026) –...
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Press ReleaseTMX Newsfile | Feb 20, 2026 7:00 AM EST This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past. Toronto, Ontario–(Newsfile Corp. – February 20, 2026) – Theralase® Tec...
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Press ReleaseTMX Newsfile | Feb 10, 2026 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – February 10, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated ...
Theralase® Provides Update on Bladder Cancer Clinical Study
Press ReleaseInterim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response Toronto, Ontario – February 4, 2026 Theralase® Technologies Inc. (“Thera...
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Press ReleaseTMX Newsfile | Feb 2, 2026 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – February 2, 2026) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company dedicated to...
Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
Press ReleaseToronto, Ontario, January 12, 2026 – Ferring Pharmaceuticals and Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) are pleased to announce that they have entered into a collaborative clinical development agreement (“Agreement”...
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Press ReleaseNewsfile | Dec 23, 2025 4:40 PM EST Toronto, Ontario–(Newsfile Corp. – December 23, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering lig...
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Press ReleaseNewsfile | Dec 12, 2025 5:00 PM EST Toronto, Ontario–(Newsfile Corp. – December 12, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering lig...
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseNewsfile | Nov 24, 2025 7:00 AM EST Toronto, Ontario–(Newsfile Corp. – November 24, 2025) – Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (“Theralase®” or the “Company“), a clinical stage pharmaceutical company pioneering lig...
Theralase® Investor Conference Call Reminder
Press ReleaseNov 17, 2025 7:00 AM EST Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response Toronto, Ontario–(Newsfile Corp. – November 17, 2025) – Theralase® Technologies ...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
